A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Chandler, Arizona 85286, United States
480-508-1038
La Jolla, California 92037, United States
Stamford, Connecticut 06905, United States
Fort Myers, Florida 33912, United States
Gainesville, Florida 32608, United States
Fairway, Kansas 66205, United States
Charlestown, Massachusetts 02129, United States
Houston, Texas 77054, United States
San Antonio, Texas 78229, United States
tabashi City, 173-0015, Japan
Gangnam-gu, 06273, South Korea
82-2-2019-3320
Namdong-gu, 21565, South Korea
760-631-3000
949-753-1663
818-398-9855
203-914-1903
561-968-2933
305-933-5993
561-374-8461
239-939-7777
407-500-5252
352-629-5800
407-337-1000
813-353-9613
561-845-0500
407-916-0060
317-963-7402
913-574-0976
401-435-8950
781-551-5812
978-831-8041
248-957-8940
417-328-7781
503-279-8252
409-331-6040
713-486-0536
512-218-1222
703-520-9703
425-899-5385
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
82-32-890-1119
82-2-2290-8374
82-2-2030-6605
82-2-2650-5298
886-2-2249-0088
886-2-2263-0588
886-6-235-3535 ext. 5892
886-2-2312-3456
886228757578
886-3-328-1200 ext. 8433